Scholarlink

<p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have become a cornerstone in the treatment of type 2 diabetes mellitus (T2DM), due to their efficacy in both glycaemic control and cardio- and nephroprotection. In contrast, their hepatic effects remain less well characterised. This review provides an overview of the currently available evidence on the impact of this class of glucose-lowering drugs in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), which represents an additional cardiovascular risk factor for patients with “cardio-renal-metabolic” syndrome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impatto degli SGLT2i sulla MASLD in pazienti con diabete mellito tipo 2

  • 期刊论文

  • 发表日期：

    2026年6月22日

查看全文
  • Natascia Tahani,
  • Massimiliano Caprio

摘要

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have become a cornerstone in the treatment of type 2 diabetes mellitus (T2DM), due to their efficacy in both glycaemic control and cardio- and nephroprotection. In contrast, their hepatic effects remain less well characterised. This review provides an overview of the currently available evidence on the impact of this class of glucose-lowering drugs in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), which represents an additional cardiovascular risk factor for patients with “cardio-renal-metabolic” syndrome.